Valiant Laboratories Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Valiant Laboratories Limited generated cash of $18,854,000, which is less than the previous year. Cash used in financing activities reached the amount of $1,524,479,000 last year. Net change in cash is therefore $104,566,000.
Cash Flow
| 2023 | 560.51M | -551.68M | -9.33M |
|---|---|---|---|
| 2024 | 18.85M | -1.43B | 1.52B |
VALIANTLAB.NS Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 12.61M | 13.12M |
Operating activities | ||
Net income | -7.69M | 381.36M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 19.65M | 15.63M |
Stock-based compensation expense | 0 | 0 |
| Deferred income tax benefit | 0 | 0 |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 428.41M | 222.00M |
Inventories | 30.27M | 27.61M |
Accounts payable | 0 | 0 |
Cash generated by operating activities | 18.85M | 560.51M |
Investing activities | ||
Purchases Of Investments | -35.93M | -336.16M |
Investments In Property Plant And Equipment | -458.70M | -376.80M |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -1.43B | -551.68M |
Financing activities | ||
Common Stock Issued | 0 | 0 |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 166.50M | -12.80M |
Cash used in financing activities | 1.52B | -9.33M |
Net Change In Cash | 104.56M | -510K |
Cash at end of period | 117.18M | 12.61M |
| Data source | Data source |